phenobarbital has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cao, F; Chen, X; Kim, TH; Ma, N; Niu, G; Sun, Z; Tong, G | 1 |
1 review(s) available for phenobarbital and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for phenobarbital and exenatide
| Article | Year |
|---|---|
PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Topics: Aminophylline; Animals; Atropine; Blotting, Western; Cardiovascular Agents; Disease Models, Animal; Drug Combinations; Exenatide; Glucagon-Like Peptide 1; Heart; Heart Function Tests; Histocytochemistry; Male; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Nitroglycerin; Papaverine; Peptides; Phenobarbital; Survival Analysis; Treatment Outcome; Venoms | 2015 |